Cancer Treatment Reviews
Volume 24, Issue 1 , Pages 35-53 , February 1998

A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer

  • Rajkumar S.V.
    • ,
  • Adjei A.A.

      Affiliations

    • Corresponding Author InformationCorrespondence: A. A. Adjei, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA

References 

  1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1997;47:5–27
  2. Ihde DC. Chemotherapy of lung cancer. N Engl J Med. 1992;327:1434–1441
  3. Strauss GM, Langer MP, Elias AD, Skarin AT, Sugarbaker DJ. Multimodality treatment of stage IIIA non-small-cell lung carcinoma: a critical review of the literature and strategies for future research. J Clin Oncol. 1992;10:829–838
  4. Hilaris BS, Nori D. The role of external radiation and brachytherapy in unresectable non-small cell lung cancer. Surg Clin North Am. 1987;67:1061–1071
  5. Perez CA, Stanley K, Grundy G, et al.  Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: report by the Radiation Therapy Oncology Group. Cancer. 1982;50:1091–1099
  6. Curran WJ, Stafford PM. Lack or apparent difference in outcome between clinically stage IIIA and IIIB non-small-cell lung cancer treated with radiation therapy. J Clin Oncol. 1990;8:409–415
  7. Perez CA, Bauer M, Edelstein S, Gillespie BW, Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys. 1986;12:539–547
  8. Martini N, Kris MG, Flehinger BJ, et al.  Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg. 1993;55:1365–1373
  9. Rosell R, Gomez-Codina J, Camps C, et al.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153–158
  10. Fossella FV, Rivera E, Roth JA. Preoperative chemotherapy for stage IIIa non-small cell lung cancer. Curr Opin Oncol. 1996;8:106–111
  11. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899–909.
  12. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. In: Results of a meta-analysis of the literature. Chest. 106:1994;p. 861–865
  13. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?. J Clin Oncol. 1993;11:1866–1872
  14. Van Zandwijk N, Giaccone G. Treatment of metastatic non-small cell lung cancer. Curr Opin Oncol. 1996;8:120–125
  15. Bonomi P. Chemotherapy for stage IV non-small cell lung cancer: protocol versus nonprotocol?. In: Is noninvestigational treatment worthwhile? Patient selection? Which regimen? What's next?. Semin Rad Oncol. 6:1996;p. 110–117
  16. Dhingra HM, Valdivieso M, Carr DT, et al.  Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer. J Clin Oncol. 1985;3:176–183
  17. Klastersky J, Sculier JP, Lacroix H, et al.  A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990;8:1556–1562
  18. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al.  Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1989;7:1602–1613
  19. Ettinger DS. New drugs for treating small cell lung cancer. Lung Cancer. 1995;12(Suppl. 3):S53–S61
  20. Ihde DC, Mulshine JL, Kramer BS, et al.  Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994;12:2022–2034
  21. Cook RM, Miller YE, Bunn PA. Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. Curr Probl Cancer. 1993;17:69–141
  22. Giaccone G. New drugs in non-small cell lung cancer. An overview. Lung Cancer. 1995;12(Suppl. 1):S155–S162
  23. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxes brevifolia. J Am Chem Soc. 1971;93:2325–2327
  24. Horwitz SB. Mechanism of action of Taxol. Trends Pharmacol Sci. 1992;13:134–136
  25. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs. 1995;6:339–355 Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs. 1995;6:363–368
  26. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med. 1995;332:1004–1014
  27. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. In: 3rd ed.. Proc Natl Acad Sci U.S.A. 90:1993;p. 9552–9556
  28. Lodish H, Baltimore D, Berk A, Zipursky SL, Matsudaira P, Darnell J. Molecular Cell Biology. In: 3rd ed.. New York: Scientific American Books, Inc; 1995;p. 1051–1123
  29. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst. 1991;83:288–291
  30. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry. 1993;32:2747–2755
  31. Riou J-F, Petitgenet O, Combeau C, Lavelle F. Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line. (abstract) In: second edition. Proc Annu Meet Am Assoc Cancer Res. 35:1994;p. 385
  32. Riou JF, Naudin A, Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun. 1992;187:164–170
  33. Belotti D, Vergani V, Drudis D, et al.  The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843–1849
  34. Verschueren H, Dewit J, De Braekeleer J, Schirrmacher V, De Baetselier P. Motility and invasive potency of murine T-lymphoma cells: effect of microtubule inhibitors. Cell Biol Int. 1994;18:11–19
  35. Stearns ME, Wang M. Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res. 1992;52:3776–3781
  36. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst. 1994;86:441–446
  37. Liebmann J, Cook JA, Teague D, et al.  Taxol mediated radiosensitization in human tumor cell lines. (abstract) In: second edition. Proc Annu Meet Am Assoc Cancer Res. 34:1993;p. 349
  38. Stromberg JS, Lee YJ, Armour EP, Martinez AA, Corry PM. Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines. Cancer. 1995;75:2262–2268
  39. Choy H, Akerley W, Safran H, Graziano S, Chung C, Cole B. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. (abstract) In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 371
  40. Wolf M, Merte H, Faoro C, Pfab R, Havemann K, Diergarten K. Dose finding study of paclitaxel and simultaneous radiotherapy in Stage III non small cell lung cancer (NSCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 14:1995;p. 348
  41. Masters GA, Haraf DJ, Hoffman PC, Golomb HM, Vokes EE. Phase I study of concomitant docetaxel (Taxotere, TXT) and radiation (RT) in advanced chest malignancies. (abstract) In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 374
  42. Gelmon K. The taxoides: paclitaxel and docetaxel. Lancet. 1994;344:1267–1272
  43. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al.  European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12:2654–2666
  44. Boehm DK, Maksymiuk AW. Paclitaxel premedication regimens. (letter to the editor) J Natl Cancer Inst. 1996;88:463–465
  45. Uziely B, Jeffers S, Muggia F. Low doses of dexamethasone protect against paclitaxel (Taxol)-related hypersensitivity reactions following cycle 1. (letter to the editor) Ann Oncol. 1994;5:474
  46. Langer CJ, Leighton JC, Comis RL, et al.  Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995;13:1860–1870
  47. Parikh B, Khanolkar S, Advani SH, Dhabhar B, Chandra M. Safety profile of single-dose dexamethasone premedication for paclitaxel. (letter to the editor) J Clin Oncol. 1996;14:2189–2190
  48. Nabholtz JM, Gelmon K, Bontenbal M, et al.  Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996;14:1858–1867
  49. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr. 1993;15:107–115
  50. Wanders J, van Oosterom AT, Gore M, et al.  Taxotere-toxicity-protective effects of premedication. Eur J Cancer. 1993;29A:S206
  51. Spencer CM, Faulds D. Paclitaxel. In: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. second edition. Drugs. 48:1994;p. 794–847
  52. Rowinsky EK, Chaudhry V, Forastiere AA, et al.  Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol. 1993;11:2010–2020
  53. Gianni L, Kearns CM, Giani A, et al.  Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995;13:180–190
  54. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 1996;56:2112–2115
  55. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res. 1994;54:386–392
  56. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of Taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol. 1987;5:1232–1239
  57. Schilder LE, Egorin MJ, Zuhowski EG, Rossof AH. The pharmacokinetics of Taxol in a dialysis patient. (abstract) In: second edition. Proc. A.S.C.O. 13:1994;p. 136
  58. Seidman AD, Hochhauser D, Gollub M, et al.  Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol. 1996;14:1877–1884
  59. Holmes FA, Valero V, Walters R, et al.  Phase III trial of paclitaxel (P) administered over 3- or 96-hr for metastatic breast cancer (MBC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 106
  60. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol. 1995;13:1609–1614
  61. Bonomi P, Kim K, Chang A, Johnson D. Phase III trial comparing etoposide (E) cisplatin (C) versus Taxol (T) with cisplatin-G-CSF (G) versus Taxol-cisplatin in advanced non-small cell lung cancer. In: An Eastern Cooperative Oncology Group (ECOG) trial. second edition. Proc Am Soc Clin Oncol. 15:1996;p. 382; (abstract)
  62. Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res. 1996;56:58–65
  63. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991;51:4845–4852
  64. Cabral F, Wible L, Brenner S, Brinkley BR. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol. 1983;97:30–39
  65. Horwitz SB, Cohen D, Rao S, Ringel I, Shen H-J, Yang C-PH. Taxol: mechanisms of action and resistance. Monogr Natl Cancer Inst. 1993;15:55–61
  66. Gupta RS. Taxol resistant mutants of Chinese hamster ovary cells: genetic biochemical, and cross-resistance studies. J Cell Physiol. 1983;114:137–144
  67. Rischin D, Webster LK, Millward MJ, et al.  Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst. 1996;88:1297–1301
  68. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst. 1993;85:388–394
  69. Murphy WK, Fossella FV, Winn RJ, et al.  Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993;85:384–388
  70. Gatzemeier U, Heckmayr M, Neuhauss R, et al.  Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer. 1995;12(Suppl 2):S101–S106
  71. Millward MJ, Bishop JF, Friendlander M, et al.  Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 1996;14:142–148
  72. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1995;13:1430–1435
  73. Kirschling RJ, Jung SH, Jett JR. A phase II trial of Taxol and G CSF in previously untreated patients with extensive stage small cell lung cancer (SCC). In: second edition. Proc Am Soc Clin Oncol. 13:1994;p. 326
  74. Belani CP, Aisner J, Hiponia D, Engstrom C. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin Oncol. 1995;22(Suppl. 9):7–12
  75. Johnson DH, Paul DM, Hande KR, DeVore RF. Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial—LUN-46. Semin. Oncol. 1995;22(Suppl. 9):30–33
  76. Langer C, Kaplan R, Rosvold E, et al.  Paclitaxel (P) by 1 hr infusion combined with carboplatin (C) in advanced non-small cell lung carcinoma (NSCLC): a Phase II study. (abstract) In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 396
  77. Vafai D, Israel V, Zaretsky S, Natale RB. Phase I/II trial of combination carboplatin and Taxol in non-small cell lung cancer (NSCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 14:1995;p. 352
  78. Paul D, DeVore RD, Hande K, et al.  Phase II trial of carboplatin (C) + paclitaxel (T) in advanced non-small cell lung cancer (NSCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 14:1995;p. 371
  79. Hainsworth JD, Thompson DS, Urba WJ, et al.  One hour paclitaxel plus carboplatin in advanced non-small cell lung cancer (NSCLC): preliminary results of a multi-institutional phase II study. (abstract) In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 379
  80. Schütte W, Bork I, Sucker S. Phase II trial of Paclitaxel and Carboplatin as firstline treatment in advanced non small cell lung-cancer (NSCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 398
  81. Sørensen JB, Wederwang K, Bjarnøe H, Dombernowsky P, Hansen HH. Biweekly paclitaxel (P) and cisplatin (C) for nonresectable non small cell lung cancer (NSCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 394
  82. Belli L, Le Chevalier T, Gottfried M, et al.  Phase I–II trial of paclitaxel (Taxor®) and cisplatin in previously untreated advanced non-small cell lung cancer (NSCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 14:1995;p. 350
  83. Giaccone G, Splinter TAW, Postmus P, van Meerbeeck J, Debruyne C, Sahmoud T. Teniposide-cisplatin vs paclitaxel-cisplatin in advanced non-small cell lung cancer (NSCLC). In: Results of a randomized phase II study of the EORTC-LCCG. second edition. Proc Am Soc Clin Oncol. 14:1995;p. 356; (abstract)
  84. Hainsworth JD, Stroup SL, Greco FA. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma. Cancer. 1996;77:2458–2463
  85. Hainsworth JO, Stroup SL, Gray JR, Meluch AL, Erland JB, Greco FA. Paclitaxel (1-hour infusion), carboplatin, and extended schedule etoposide in small cell lung cancer (SCLC): a second generation phase II study. (abstract) In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 400
  86. Cerny T, Kaplan S, Pavlidis N, et al.  Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer. 1994;70:384–387
  87. Francis PA, Rigas JR, Kris MG, et al.  Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol. 1994;12:1232–1237
  88. Fossella FV, Lee JS, Murphy WK, et al.  Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol. 1994;12:1238–1244
  89. Fossella FV, Lee JS, Shin DM, et al.  Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol. 1995;13:645–651
  90. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol. 1996;14:1649–1655
  91. Burris H, Eckardt J, Fields S, et al.  Phase II trials of Taxotere in patients with non-small cell lung cancer. In: second edition. Proc Am Soc Clin Oncol. 12:1993;p. 335
  92. Smyth JF, Smith IE, Sessa C, et al.  Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer. 1994;30A:1058–1060
  93. Cole JT, Gralla RJ, Marques CB, Rittenberg CN. Phase I–II study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer (NSCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 14:1995;p. 357
  94. Zalcberg JR, Bishop JF, Millward MJ, et al.  Preliminary results of the first Phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 14:1995;p. 351
  95. Le Chevalier T, Belli L, Monnier A, et al.  Phase II study of docetaxel (Taxotere®) and cisplatin in advanced non small cell lung cancer (NSCLC): an interim analysis. (abstract) In: second edition. Proc Am Soc Clin Oncol. 14:1995;p. 350
  96. Giaccone G, Splinter T, Postmus P, et al.  Paclitaxel-cisplatin versus teniposide-cisplatin in advanced non-small cell lung cancer (NSCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 373
  97. Smit EF, Kloosterziel C, Groen HJM, Postmus PE. A Phase II study of paclitaxel (P) in heavily pretreated patients with small cell lung cancer (SCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 394
  98. Smyth JF, Smith IE, Sessa C, et al.  Activity of docetaxel (Taxotere) in small cell lung cancer. In: The Early Clinical Trials Group of the EORTC. second edition. Eur J Cancer. 30A:1994;p. 1058–1060
  99. Pommier Y. Eukaryotic DNA topoisomerase I: genome gate-keeper and its intruders, camptothecins. Semin Oncol. 1996;23(Suppl. 3):3–10
  100. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci. 1992;81:676–684
  101. Rivory LP, Riou JF, Haaz MC, et al.  Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res. 1996;56:3689–3694
  102. Abigerges D, Armand JP, Chabot GG, et al.  Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst. 1994;86:446–449
  103. Negoro S, Fukuoka M, Masuda N, et al.  Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst. 1991;83:1164–1168
  104. Rivory LP, Chatelut E, Canal P, Mathieu-Boue A, Robert J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res. 1994;54:6330–6333
  105. Canal P, Gay C, Dezeuze A, et al.  Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. In: Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. second edition. J Clin Oncol. 14:1996;p. 2688–2695
  106. Lokiec F, Canal P, Gay C, et al.  Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol. 1995;36:79–82
  107. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru D. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn. 1991;14:341–349
  108. Armand JP. CPT-11: clinical experience in phase I studies. Semin Oncol. 1996;23(Suppl. 3):27–33
  109. Pitot HC, Erlichman C, Goldberg RM, et al.  Phase I trial of irinotecan (CPT-11) given once every three weeks to patients with advanced solid tumors. In: second edition. Proc Am Soc Clin Oncol. 15:1993;p. 494
  110. Rothenberg ML. CPT-11: an original spectrum of clinical activity. Semin Oncol. 1996;23(Suppl. 3):21–26
  111. Erlichman C, Svingen PA, Mullany SA, Kauffmann SH. Synergistic interaction of SN-38 and 5FU/Leucovorin. (abstract) In: second edition. Proc Am Assoc Cancer Res. 37:1996;p. 294
  112. Schleucher N, Harstrick A, Stahl M, Achterrath W, Wilke H, Seeber S. Evaluation of the interactions of SN-38, a topoisomerase I inhibitor and various cytotoxic agents in established human colorectal and lung cardinoma cell lines. (abstract) In: second edition. Proc Am Assoc Cancer Res. 37:1996;p. 288
  113. O'Reilly S, Rowinsky EK, Slichenmyer W, et al.  Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol. 1996;14:3062–3073
  114. Schiller JH, Kim K, Hutson P, et al.  Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol. 1996;14:2345–2352
  115. O'Reilly S, Rowinsky E, Slichenmyer W, et al.  Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst. 1996;88:817–824
  116. Kaufmann SH, Peereboom D, Buckwalter CA, et al.  Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst. 1996;88:734–741
  117. Fukuoka M, Niitani H, Suzuki A, et al.  A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 1992;10:16–20
  118. Masuda N, Fukuoka M, Kusunoki Y, et al.  CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10:1225–1229
  119. Negoro S, Fukuoka M, Niitani H, Taguchi T. Phase II study of CPT-11, a new camptothecin derivative, in small cell lung cancer (SCLC). In: second edition. Proc Am Soc Clin Oncol. 10:1991;p. 241
  120. Masuda N, Fukuoka M, Takada M, et al.  CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol. 1992;10:1775–1780
  121. Nakagawa K, Fukuoka M, Niitani H. Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 12:1993;p. 332
  122. Fujiwara Y, Yamakido M, Fukuoka M, et al.  Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in patients with small cell lung cancer (SCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 13:1994;p. 335
  123. Lynch TJ, Kalish L, Strauss G, et al.  Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol. 1994;12:347–352
  124. Perez-Soler R, Fossella FV, Glisson BS, et al.  Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol. 1996;14:503–513
  125. Ardizzoni A, Hansen H, Dombernowsky P, et al.  Phase II study of topotecan in pretreated small cell lung cancer (SCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 13:1994;p. 336
  126. Moore M, Anderson J, Burris H, et al.  A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer. (abstract) In: second edition. Proc Am Soc Clin Oncol. 14:1995;p. 199
  127. Guchelaar HJ, Richel DJ, van Knapen A. Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev. 1996;22:15–31
  128. Underhill C, Parnis FX, Highley M, et al.  A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer (EOC). (Abstract) In: second edition. Proc ASCO. 15:1996;p. 290
  129. Carmichael J, Possinger K, Phillip P, et al.  Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol. 1995;13:2731–2736
  130. Catimel G, Vermorken JB, Clavel M, et al.  A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol. 1994;5:543–547
  131. Moore MJ, Tannock I, Ernst S, Huan S, Murray N. Gemcitabine demonstrates promising activity as a single agent in the treatment of metastatic transitional cell carcinoma. (abstract) In: second edition. Proc ASCO. 15:1996;p. 250
  132. Hertel LW, Boder GB, Kroin JS, et al.  Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. 1990;50:4417–4422
  133. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs. 1995;6(Suppl. 6):7–13
  134. Bouffard DY, Laliberte J, Momparler RL. Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol. 1993;45:1857–1861
  135. Heinemann V, Xu YZ, Chubb S, et al.  Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol. 1990;38:567–572
  136. Heinemann V, Xu YZ, Chubb S, et al.  Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res. 1992;52:533–539
  137. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22(Suppl. 11):3–10
  138. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst. 1996;88:1193–1203
  139. Sorensen JB. Gemcitabine in non-small cell lung cancer. Lung Cancer. 1995;12(Suppl. 1):S173–S175
  140. Green MR. Gemcitabine safety overview. Semin Oncol. 1996;23(Suppl. 10):32–35
  141. Plunkett W. Pharmacology of gemcitabine. (abstract) Ann Oncol. 1992;3:198
  142. Allerheiligen S, Johnson R, Hatcher B, et al.  Gemcitabine pharmacokinetics are influenced by gender, body surface area (BSA), and duration of infusion. (abstract) In: second edition. Proc Am Soc Clin Oncol. 13:1994;p. 136
  143. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996;23(Suppl. 10):3–15
  144. Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD, Culp HW. Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos. 1992;20:849–855
  145. Shepherd FA, Goss PE, Latreille J, et al.  A phase II study of ifosfamide, cisplatin, etoposide in patients with advanced non-small cell lung cancer: a preliminary report. Semin Oncol. 1990;17(Suppl. 4):19–23
  146. Abbruzzese JL, Grunewald R, Weeks EA, et al.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491–498
  147. Fossella FV, Lippman SM, Shin DM, et al.  Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997;15:310–316
  148. Brown T, O'Rourke T, Burris H, et al.  A phase I trial of gemcitabine (LY188011) administered intravenously every two weeks. In: second edition. Proc Am Soc Clin Oncol. 10:1991;p. 115
  149. Poplin EA, Corbett T, Flaherty L, et al.  Difluorodeoxycytidine (dFdC)—gemcitabine: a phase I study. Invest New Drugs. 1992;10:165–170
  150. O'Rourke TJ, Brown TD, Havlin K, et al.  Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. (letter to the editor) Eur J Cancer. 1994;30A:417–418
  151. Anderson H, Thatcher N, Walling J, Hansen H. A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer. 1996;74:460–462
  152. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol. 1995;22(Suppl. 11):72–79
  153. Peters GJ, Ruiz van Haperen VW, Bergman AM, et al.  Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol. 1996;23(Suppl. 10):16–24
  154. Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol. 1996;24:1340–1346
  155. Yamaji Y, Nakamura H, Fujita T, Fujita J, Takahara J. Remarkable difference in growth inhibitory effect of gemcitabine on various human lung cancer cell lines. (abstract) In: second edition. Proc Am Assoc Cancer Res. 36:1995;p. 407
  156. Anderson H, Thatcher N, Walling J, Lund B. Gemcitabine and palliation of symptoms in non-small cell lung cancer. In: second edition. Proc Am Soc Clin Oncol. 13:1995;p. 367
  157. Fossella FV, Lippman SM, Tarassoff P, et al.  Phase I/II study of gemcitabine, an active agent for advanced non-small cell lung cancer (NSCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 14:1995;p. A1144
  158. Gatzemeier U, Shepherd FA, Le Chevalier T, et al.  Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer. 1996;32A:243–248
  159. Abratt R, Bezwoda W, Falkson G, Goedhals L, Hacking D, Rugg T. Efficacy and safety of gemcitabine in non small cell lung cancer (NSCLC): Phase II study results. (abstract) In: second edition. Proc Am Soc Clin Oncol. 12:1993;p. 338
  160. Cormier Y, Eisenhauer E, Muldal A, et al.  Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). In: A study of the National Cancer Institute of Canada Clinical Trials Group. second edition. Ann Oncol. 5:1994;p. 283–285
  161. Sandler AB, Ansari R, McClean J, Fisher W, Dorr A, Einhorn LH. A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small cell lung cancer (NSCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 14:1995;p. 357
  162. Crino L, Scagliotti G, Marangolo M, et al.  Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1997;15:297–303
  163. Anton A, Carrato A, Gonzalez Larriba JL, et al.  Phase II activity of gemcitabine in combination with cisplatin in advanced non-small cell lung cancer (NSCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 380
  164. Shepherd F, Cormier Y, Evans W, et al.  A phase II study of gemcitabine and cisplatin weekly × 3 every 4 weeks in patients with non-small cell lung cancer (NSCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 380
  165. Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Gemcitabine and cisplatin for advanced non-small cell lung cancer (NSCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 380
  166. Crawford J. Update: vinorelbine (Navelbine) in non-small cell lung cancer. Semin Oncol. 1996;23(Suppl. 5):2–7
  167. Binet S, Chaineau E, Fellous A, et al.  Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer. 1990;46:262–266
  168. Urien S, Bree F, Breillout F, Bastian G, Krikorian A, Tillement JP. Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood. Cancer Chemother Pharmacol. 1993;32:231–234
  169. Robieux I, Sorio R, Galliogioni E, et al.  Pharmacokinetics of vinorelbine in elderly patients with metastatic breast cancer. (abstract) Ann Oncol. 1994;5(Suppl. 8):58
  170. Leveque D, Jehl F, Quoix E, Breillout F. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J Clin Pharmacol. 1992;32:1096–1098
  171. Chang A, DeVore R, Gu C, Johnson D, Keng P, Asbury R. Paclitaxel (P) and Vinorelbine (V) combination in advanced non-small cell lung cancer (NSCLC); in vitro and clinical studies. (abstract) In: second edition. Proc Am Assoc Cancer Res. 37:1996;p. 168
  172. Aoe K, Ueoka H, Kiura K, et al.  Synergistic effect of docetaxel (DCT) and vinorelbine (VNB) against in vitro growth of a human small-cell lung cancer cell line. (abstract) In: second edition. Proc Am Assoc Cancer Res. 37:1996;p. 375
  173. Gomi K, Ohno H, Nomura K, Okabe M, Kobayashi K, Niitani H. Kinetic analysis of combination effect of Navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture. Jpn J Cancer Res. 1992;83:532–539
  174. Adams DJ, Knick VC. P-glycoprotein mediated resistance to 5′-nor-anhydro-vinblastine (Navelbine). Invest New Drugs. 1995;13:13–21
  175. Debal V, Allam N, Morjani H, et al.  Recovery from damages to microtubules in a bladder carcinoma cell line resistant to vinorelbine (Navelbine). (abstract) In: second edition. Proc Am Assoc Cancer Res. 35:1994;p. 400
  176. Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol. 1991;14:115–119
  177. Furuse K, Kubota K, Kawahara M, et al.  A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group Lung Cancer. 1994;11:385–391
  178. Depierre A, Le Chevalier T, Quoix E, et al.  Phase II study of Navelbine (NVB) in small cell lung cancer (SCLC). (abstract) In: second edition. Proc Am Soc Clin Oncol. 14:1995;p. 348
  179. Adam Z, Coupkova H, Kolek V, et al.  Vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter Czech study. Acta Med Austriaca. 1995;22:120–124
  180. Frontini L, Candido P, Cattaneo MT, et al.  Cisplatin-vinorelbine combination chemotherapy in locally advanced non-small cell lung cancer. Tumori. 1996;82:57–60
  181. Berthaud P, Le Chevalier T, Ruffie P, et al.  Phase-I–II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer. 1992;28A:1863–1865
  182. Pronzato P, Ghio E, Losardo PL, Landucci M, Vaira F, Vigani A. Carboplatin and vinorelbine in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 1996;37:610–612
  183. Le Chevalier T, Brisgand D, Douillard JY, et al.  Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994;12:360–367
  184. Wozniak AJ, Crowley JJ, Balcerzak SP, et al.  Randomized phase III trial of cisplatin (CDDP) vs CDDP plus Navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): report of a Southwest Oncology Group study (SWOG-9308). (abstract) In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 374
  185. Depierre A, Chastang C, Quoix E, et al.  Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol. 1994;5:37–42
  186. Gil Deza E, Balbiani L, Coppola F, et al.  Phase III study of Navelbine (NVB) vs NVB plus cisplatin in non small cell lung cancer (NSCLC) Stage IIIB or IV. (abstract) In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 394
  187. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, et al.  Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group Eur J Cancer. 1993;29A:1720–1722
  188. Furuse K, Kubota K, Kawahara M, et al.  Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group Oncology. 1996;53:169–172

PII: S0305-7372(98)90070-6

Cancer Treatment Reviews
Volume 24, Issue 1 , Pages 35-53 , February 1998

Article Tools